Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
133.41
-3.71 (-2.71%)
At close: Mar 28, 2025, 4:00 PM
132.01
-1.40 (-1.05%)
Pre-market: Mar 31, 2025, 8:31 AM EDT
Repligen Revenue
In the year 2024, Repligen had annual revenue of $634.44M with 0.33% growth. Repligen had revenue of $167.55M in the quarter ending December 31, 2024, with 0.56% growth.
Revenue (ttm)
$634.44M
Revenue Growth
+0.33%
P/S Ratio
11.76
Revenue / Employee
$356,827
Employees
1,778
Market Cap
7.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RGEN News
- 11 days ago - Repligen: Ongoing Bioprocessing Market Recovery - Seeking Alpha
- 26 days ago - 908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth - Benzinga
- 27 days ago - Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices - Business Wire
- 5 weeks ago - Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook - Benzinga
- 6 weeks ago - Repligen to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Repligen Launches the CTech™ SoloVPE® PLUS System - GlobeNewsWire